Ruxolitinib phosphate-laden nanoemulgel: amelioration of ex vivo permeation and in vivo therapeutic efficacy for the effective therapeutic management of psoriasis
Inflammopharmacology · 2026-07 · 34 (7) · 4831-4850
DOI: 10.1007/s10787-026-02286-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammopharmacology, online erschienen am 12.06.2026. Verfasst von Ratnam Sreya und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pha…. Hauptthemen laut MEDLINE: Psoriasis, Pyrazoles, Nanoparticles. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
Psoriasis is a chronic, immune-driven inflammatory skin ailment marked by recurrent flare-ups. Ongoing clinical investigations are focused on therapeutic strategies that modulate key signaling pathways implicated in disease pathogenesis. Ruxolitinib (RUX) is a Janus kinase 1/2 inhibitor approved for several hematological and inflammatory disorders, is being clinically investigated as a potential therapeutic option for psoriasis. The current study reports the formulation, characterization, and assessment of in vitro, ex vivo, and in vivo efficacy of RUX-loaded nanoemulgel (RUX NEG) for the management of psoriasis. The spontaneous emulsification method was employed to prepare RUX-loaded nanoemulsion, which has shown a droplet size of 50.35 ± 1.05 nm with a polydispersity index of 0.20 ± 0.01. Further, RUX-loaded nanoemulsion incorporated in a gel matrix to form a RUX-NEG that has shown pseudoplastic shear thinning behaviour. Meanwhile, ex vivo permeation of RUX-NEG demonstrated steady-state flux and significantly higher retention (74.12 ± 13.56 µg/g) of RUX in epidermal skin layers than that of plain gel (52.39 ± 8.69 µg/cm2/h). Moreover, in vivo therapeutic efficacy was evaluated in an imiquimod-induced psoriasis model in mice, which revealed that RUX-NEG significantly attenuated the severity index score and psoriasis area, as well as inflammatory cytokine levels such as IL-17, IL-22, and IL-23, by 3.82-, 2.29-, and 2.71-fold compared with the negative control. Histopathological changes also confirmed improvement in skin condition after treatment with the RUX-NEG formulation compared with the negative control. These findings concluded potential improvement in the anti-inflammatory activity of RUX after loading into nanoemulgel for the effective management of psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, 5000…
Zitieren
APA
Sreya, R., Nene, S., Pathade, V., Vambhurkar, G., Phatale, V., & Srivastava, S. (2026). Ruxolitinib phosphate-laden nanoemulgel: amelioration of ex vivo permeation and in vivo therapeutic efficacy for the effective therapeutic management of psoriasis. Inflammopharmacology, 34(7), 4831-4850. https://doi.org/10.1007/s10787-026-02286-3
Vancouver
Sreya R, Nene S, Pathade V, Vambhurkar G, Phatale V, Srivastava S. Ruxolitinib phosphate-laden nanoemulgel: amelioration of ex vivo permeation and in vivo therapeutic efficacy for the effective therapeutic management of psoriasis. Inflammopharmacology. 2026;34(7):4831-4850. doi:10.1007/s10787-026-02286-3
BibTeX
@article{Sreya2026,
author = {Sreya, Ratnam and Nene, Shweta and Pathade, Vrushali and Vambhurkar, Ganesh and Phatale, Vivek and Srivastava, Saurabh},
title = {Ruxolitinib phosphate-laden nanoemulgel: amelioration of ex vivo permeation and in vivo therapeutic efficacy for the effective therapeutic management of psoriasis},
journal = {Inflammopharmacology},
year = {2026},
volume = {34},
number = {7},
pages = {4831--4850},
doi = {10.1007/s10787-026-02286-3}
}
EUVIMED